You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Researchers used whole-genome shotgun metagenomic sequencing to home in on specific bacteria associated with patients' response to immune checkpoint inhibitor treatment.
The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.
Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.
The collaboration will test the effects of using human microbiome-derived bacteria alongside immune checkpoint inhibitor nivolumab to treat advanced metastatic cancers.
Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.